Results 21 to 30 of about 3,363,784 (294)
PD-L2 Is Constitutively Expressed in Normal and Malignant Urothelium
Frontiers in Oncology, 2021 The use of immune checkpoint blockade, in particular PD-1 and PD-L1 inhibitors, is now commonplace in many clinical settings including the treatment of muscle-invasive bladder cancer (MIBC).
Alexander C. Dowell +9 more
doaj +1 more source
Predictive and prognostic biomarkers of Bacillus Calmette-Guérin therapy failure in bladder cancer patients: A systematic review. [PDF]
Mol OncolHigh‐risk bladder cancer is typically treated with Bacillus Calmette‐Guérin (BCG), but 30–40% of patients relapse. No FDA‐ or CE‐approved biomarkers currently predict or prognosticate BCG failure. We systematically reviewed the literature and identified 72 eligible studies, revealing several promising biomarkers associated with BCG treatment response ...
Ribeiro-Pereira R +7 more
europepmc +2 more sources
European Urology Open Science, 2023 Enfortumab vedotin (EV) is an antibody-drug conjugate approved for the treatment of refractory advanced urothelial cancer. Cutaneous toxicity is well described but has not been correlated with response.
Evangelia Vlachou +6 more
doaj +1 more source
Properties of non-coding mutation hotspots as urinary biomarkers for bladder cancer detection
Scientific Reports, 2023 Mutations at specific hotspots in non-coding regions of ADGRG6, PLEKHS1, WDR74, TBC1D12 and LEPROTL1 frequently occur in bladder cancer (BC). These mutations could function as biomarkers for the non-invasive detection of BC but this remains largely ...
L. Baxter +14 more
doaj +1 more source
Oncology and Therapy, 2023 In this plain language podcast, highlights from the European Society for Medical Oncology (ESMO) Congress are discussed for a second year in a row, from the perspective of both a patient advocate and a healthcare professional.
Alex Filicevas, Thomas Powles
doaj +1 more source
Annals of Urologic Oncology, 2021 Introduction To evaluate the response of patients with high-risk bacillus Calmette-Guerin (BCG)–unresponsive non-muscle invasive bladder cancer (NMIBC) who we treated with intravesical CG0070, a conditionally replicating granulocyte macrophage colony ...
Evan Austin +3 more
doaj +1 more source
An Intravesical Akkermansia muciniphila-Based Chemo-Immunotherapeutic Platform for Bladder Cancer. [PDF]
Adv Sci (Weinh)Pasteurized Akkermansia muciniphila is engineered into an intravesical F127/doxorubicin platform that couples localized chemotherapy with immune remodeling. By inducing apoptosis, ferroptosis, and immunogenic cell death, this chemo‐immunotherapeutic system enhances dendritic‐cell maturation, antigen cross‐presentation, and tumor‐specific CD8+ T‐cell ...
Li R +11 more
europepmc +2 more sources
Human urinary exosomes in bladder cancer patients : properties, concentrations and possible clinical application [PDF]
, 2015 OBJECTIVE: High grade bladder cancer is extremely aggressive. Early detection is thus an important challenge. De- velopment of non-invasive diagnostic tools particularly using urine samples could be of importance in the diagnosis and surveillance of ...
Mullen, Peter +11 more
core +1 more source
Schistosomiasis and Urinary Bladder Cancer in North Western Tanzania: A Retrospective Review of 185 Patients. [PDF]
, 2013 Worldwide, cancers of the urinary bladder are well known to be associated with environmental chemical carcinogens such as smoking and occupational exposure to polycyclic aromatic hydrocarbons.
Chalya, Philipo L +5 more
core +1 more source
European Urology Open Science, 2023 Background: Grade of non–muscle-invasive bladder cancer (NMIBC) is an important prognostic factor for progression. Currently, two World Health Organization (WHO) classification systems (WHO1973, categories: grade 1–3, and WHO2004 categories: papillary ...
Irene J. Beijert +28 more
doaj +1 more source